Soleno Therapeutics, Inc. (SLNO)
After hours:
| Previous close | 0.9574 |
| Open | 0.9800 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1100 |
| Day's range | 0.9100 - 0.9800 |
| 52-week range | 0.9000 - 9.4500 |
| Volume | |
| Avg. volume | 67,714 |
| Market cap | 7.425M |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3470 |
| Earnings date | 09 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
- GlobeNewswire
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2022. Third Quarter 2022 and Recent Corporate Highlights Initiated the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Chol
- Zacks
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why
Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.
- GlobeNewswire
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). “Initiation of the randomized withdrawal per
